Biocon-Viatris Biosimilars Combine: Deal Or No Deal?

Are Viatris and long-standing partner Biocon mulling a consolidation of their biosimilars business? Some analysts suggest any deal that positions Viatris as a minority stakeholder in a potential combine doesn’t bode well for the US firm.